These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1666493)

  • 1. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
    Stals FS; de Clercq E; Bruggeman CA
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2262-6. PubMed ID: 1666493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.
    Stals FS; Zeytinoglu A; Havenith M; de Clercq E; Bruggeman CA
    Antimicrob Agents Chemother; 1993 Feb; 37(2):218-23. PubMed ID: 8383939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
    Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
    Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).
    Neyts J; Snoeck R; Schols D; Balzarini J; De Clercq E
    Virology; 1990 Nov; 179(1):41-50. PubMed ID: 2171213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro.
    Neyts J; Snoeck R; Balzarini J; De Clercq E
    Antiviral Res; 1991 Jul; 16(1):41-52. PubMed ID: 1663729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication.
    Snoeck R; Sakuma T; De Clercq E; Rosenberg I; Holy A
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1839-44. PubMed ID: 2854454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.
    Neyts J; Sobis H; Snoeck R; Vandeputte M; De Clercq E
    Eur J Clin Microbiol Infect Dis; 1993 Apr; 12(4):269-79. PubMed ID: 8390357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC.
    Kloover JS; Vanagt WY; Stals FS; Bruggeman CA
    Antiviral Res; 1997 Jul; 35(2):105-12. PubMed ID: 9217247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique.
    Snoeck R; Schols D; Andrei G; Neyts J; De Clercq E
    Antiviral Res; 1991 Jul; 16(1):1-9. PubMed ID: 1663725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro.
    Shigeta S; Konno K; Baba M; Yokota T; De Clercq E
    J Infect Dis; 1991 Feb; 163(2):270-5. PubMed ID: 1846389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.
    Neyts J; Balzarini J; Naesens L; De Clercq E
    J Med Virol; 1992 May; 37(1):67-71. PubMed ID: 1320099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system.
    Moore MR; Hamzeh FM; Lee FE; Lietman PS
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2404-8. PubMed ID: 7840578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
    Neyts J; De Clercq E
    Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment of the host cell with 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is sufficient for its antiviral effect.
    Otová B; Votruba I; Holý A
    Acta Virol; 1992 May; 36(3):313-9. PubMed ID: 1360759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
    De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD
    Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors.
    Bedard J; May S; Barbeau D; Yuen L; Rando RF; Bowlin TL
    Antiviral Res; 1999 Feb; 41(1):35-43. PubMed ID: 10321577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
    De Clercq E
    Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid protein A binding radioimmunoassay for the evaluation of antiviral agents.
    Gangopadhyay NN; Whitley RJ; Chatterjee S
    J Virol Methods; 1994 Jul; 48(2-3):273-9. PubMed ID: 7527404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir.
    Bedard J; May S; Lis M; Tryphonas L; Drach J; Huffman J; Sidwell R; Chan L; Bowlin T; Rando R
    Antimicrob Agents Chemother; 1999 Mar; 43(3):557-67. PubMed ID: 10049267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC.
    Bruning JH; Persoons M; Lemström K; Stals FS; De Clercq E; Bruggeman CA
    Transpl Int; 1994; 7 Suppl 1():S365-70. PubMed ID: 11271253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.